Journal of Transplantation / 2013 / Article / Tab 3

Review Article

Everolimus in Heart Transplantation: An Update

Table 3

Results of intravascular ultrasound (IVUS) substudies in randomized trials of everolimus with reduced-exposure cyclosporine versus MMF with standard-exposure cyclosporine.

ParameterA2310 [9]B253 [2, 20]
MMFEverolimus 1.5 mg valueAzathioprineEverolimus 1.5 mg/3.0 mg value

Number of patients
 12 months101887270/69
 24 months6045/44
Mean change in MIT from baseline, mm
 12 months <0.000.100.04/0.030.01/0.003
 24 months10.150.07/0.060.014/0.004
Patients with CAV, %
 12 months 26.712.50.01852.835.7/30.40.045/0.01
 24 months58.333.3/45.50.017/n.s.

CAV: cardiac allograft vasculopathy, defined as a change in MIT ≥ 0.5 mm as assessed by intravascular ultrasound (IVUS); MIT: maximal intimal thickness; MMF: mycophenolate mofetil.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.